Introduction
============

Natural products of plants provide an abundant source of potentially active compounds for the treatments of different disorders ([@b1-ijo-48-05-1886],[@b2-ijo-48-05-1886]). Far Eastern, Middle Eastern, Saharan, and tropical regions are among the richest sources of natural products in the world. The isolation and purification of active fractions and active ingredients among potentially active natural products has received increased scientific and industrial interest ([@b2-ijo-48-05-1886]).

Red yeast rice (RYR), a Chinese dietary product made by fermenting ordinary rice with the mold *Monascus purpureus*, has been widely used as a food condiment and colorant in several Asian countries ([@b3-ijo-48-05-1886]). RYR has been used for centuries without any reports of health hazards or long-term toxicity ([@b4-ijo-48-05-1886]). Several medicinally active ingredients were isolated from RYR including monacholin-K, mevinolin (MVN; lovastatin), γ-aminobutyric acid, di-merumic acid, sterols (β-sitosterol, campesterol, stigmasterol and sapogenin), isoflavones and mono-unsaturated fatty acids ([@b3-ijo-48-05-1886],[@b4-ijo-48-05-1886]).

MVN or lovastatin is a potent HMGCo-A reductase enzyme inhibitor that has been shown to interfere with *de novo* steroidogenesis ([@b5-ijo-48-05-1886]). MVN was used clinically for the treatment of hypercholesterolemia with extremely good patient tolerance profiles ([@b6-ijo-48-05-1886],[@b7-ijo-48-05-1886]). In the last decade, epidemiological studies ([@b8-ijo-48-05-1886]) have drawn attention to the possible beneficial roles of HMGCo-A reductase inhibitors (statins), such as MVN, in neoplastic disorders. Some members of the statin group may reduce the recurrence of cancer after radical prostatectomy ([@b9-ijo-48-05-1886]). Additionally, a marked reduction in the incidence of lipoma was observed for statin-treated patients ([@b10-ijo-48-05-1886]). Of note, a negative association was reported between the use of HMGCo-A reductase inhibitors and cancer incidence in veteran populations ([@b11-ijo-48-05-1886]). Investigators focused on the ability of MVN and other statins to sensitize tumor cells for conventional chemo-therapeutics ([@b12-ijo-48-05-1886]).

Previous experimental reports manifested a potential anti-cancer activity of MVN and other HMGCo-A reductase inhibitors *per se* ([@b13-ijo-48-05-1886]). However, the exact signaling mechanisms involved in MVN-induced cell death remain controversial. Few reports attribute the anti-cancer activity of MVN to the induction of apoptosis ([@b14-ijo-48-05-1886]), while other studies negate any role of apoptosis in MVN-induced cell death ([@b15-ijo-48-05-1886]). Thus, whether the apoptotic pathway is involved in MVN-induced cytotoxicity, or not, remained an open issue by 2012. The resolution of the mechanism of MVN may improve understanding of its anti-cancer effects and suggest the likelihood of the emergence of resistance among cancer cell lines.

MVN has been shown to inhibit cell proliferation and induce apoptosis and necrosis in several experimental settings including that of breast cancer, thus making them potential anticancer agents. Multisignaling distortion effects have been observed by statin treatment. Klawitter *et al* suggested that the anti-proliferative and apoptotic effects of statins on breast cancer cells occurs due to the induction effect on reactive oxygen species (ROS). Additionally, statins increase the level of nitric oxide (NO) through the induction of inducible nitric oxide synthase (iNOS) ([@b14-ijo-48-05-1886]).

In the present study, the expression of markers of apoptosis was investigated in response to MVN treatment in MCF-7 breast cancer cells. Microarrays tested the transcript abundances of thousands of genes. The involvement of several regulatory pathways in the cytotoxic effects of MVN on breast cancer cell lines was shown. A model for the plausible mode-of-action of MVN-mediated *in vitro* cytotoxicity against breast cancer was also described.

Materials and methods
=====================

Chemicals and drugs
-------------------

Doxorubicin (DOX) is a cytotoxic anthracycline originally isolated from *Streptomyces peucetius* which has been used as a chemotherapeutic agent. DOX was used as a positive control in quantitative polymerase chain reaction (qPCR) and caspase-3 (EC 3.4.22.56) experiments. DOX and MVN were purchased from Sigma Aldrich Chemical Co. (St. Louis, MO, USA). RPMI-1640 media, fetal bovine serum and other cell culture materials were purchased from Fisher Scientific, Cell Culture (Houston, TX, USA). Other reagents were of the highest analytical grade available.

Cell culture
------------

Human transformed cell lines, from the breast (MCF-7) line were obtained from Vacsera (Giza, Egypt). Vacsera identified the cell line prior to conducting these studies. The cells were maintained in RPMI-1640 supplemented with 100 μg/ml streptomycin, 100 μg/ml penicillin and 10% (w/v) heat-inactivated fetal bovine serum in a humidified, 5% (v/v) CO~2~ atmosphere incubator at 37°C.

Cytotoxicity assays
-------------------

The cytotoxicity of MVN was tested against MCF-7 cells using an MTT assay. Exponentially growing cells were collected using 0.25% (w/v) trypsin-EDTA and plated in 96-well plates at 2.0×10^3^ cells/well. After 24 h incubation, the cells were exposed to each test compound for 72 h and washed with phosphate-buffered saline (PBS). Then, fresh 100 μl media with 10 μl MTT at 5 mg/ml in PBS were added. After overnight incubation the colored form of Heidenhain\'s Azan trichrome stain was dissolved in 100 μl of 10% (w/v) SDS and the absorbance at 570 nm was determined using a multi-detection microplate reader. The cell viability was presented as a percentage of the control.

Data analysis
-------------

The dose response curve of compounds was analyzed using the E~max~ model:
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R was the residual unaffected fraction (the resistance fraction), \[D\] was the drug concentration used, K~d~ was the drug concentration that produces a 50% reduction of the maximum inhibition rate, and m was a Hill-type coefficient. The IC~50~ was defined as the drug concentration required to reduce absorbance to 50% of that of the control (i.e., K~d~=IC~50~ when R was 0 and E~max~ was 100-R) ([@b16-ijo-48-05-1886]).

Caspase-3 activity in MCF-7 treated cells with IC~50~ of DOX and MVN
--------------------------------------------------------------------

Cells were harvested after treatment for 72 h with the pre-determined IC~50~ of DOX and MVN. Caspase-3 activity was determined using a Quantikine-immunoassay™ kit (R&D Systems, Inc., Minneapolis, MN, USA) according to the manufacturer\'s instructions. Plates were then read at 450 nm with wavelength correction at 540 nm using microwell-plate absorbance reader (ELx 808; Bio-Tek Instruments, Inc., Winooski, VT, USA). A standard curve was constructed and the amount of active caspase-3 in the treated samples was calculated.

Microarray analysis for MVN-treated MCF-7 cells RNA isolation
-------------------------------------------------------------

MCF-7 cells were resuspended at a concentration of 2.0×10^4^ cells/ml after 24 h incubation. The cells were treated with or without MVN IC~50~ for 4 h. Total RNA was extracted from the cells using 1 ml of Isogen™ (Nippon Gene Co., Ltd., Tokyo, Japan) following the manufacturer\'s instructions. Isolated RNA was ethanol precipitated, quantified and quality assessed by a Nano-Drop 2000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). Total RNA (500 ng) was used for reverse transcription when the OD~260~/OD~280~ ratio was 1.8--2.0. RNA samples were prepared as duplicates. The experiments were repeated.

cDNA synthesis, labeling and target preparation
-----------------------------------------------

cDNA was produced from total RNA using the GeneAtlas™ 3′ IVT Express kit (Affymetrix, Inc., Santa Clara, CA, USA) according to the manufacturer\'s instructions. Second-strand cDNA synthesis, biotin-labeled aRNA synthesis (IVT Labeling) and RNA fragmentation were performed by Affymetrix GeneAtlas^®^ kit reagents according to the procedure described in The GeneAtlas™ 3′ IVT Express kit User Manual.

Target hybridization and scanning
---------------------------------

Biotin-labeled and fragmented target RNA samples were loaded into Affymetrix HG-U219 Array Strip^®^ (Affymetrix, Inc.) together with poly-A control RNA and the oligomer B2. The hybridization procedure was conducted at 45°C for 16 h in the GeneAtlas™ Hybridization Station. The washing and staining procedure was performed in a GeneAtlas™ Fluidics Station with phycoerythrin-conjugated streptavidin (SAPE) according to the manufacturer\'s instructions. The GeneAtlas™ Imaging Station was used for scanning the arrays, exactly as described in the Affymetrix GeneAtlas^®^ protocol.

Preliminary analysis of the scanned chips
-----------------------------------------

Analysis was performed using Partek Express software (Ryoka Systems Inc., Tokyo, Japan) which estimates gene significance difference by ANOVA. The quality of gene expression data was checked according to quality control criteria. Pathway Studio^®^ Explore, Affymetrix Edition Version 1.1 software (Affymetrix, Inc.) was used for further data analysis and evaluation. Pathway Studio^®^ Explore is a powerful visualization and analysis solution designed for use with genomic expression data.

Statistical analysis
--------------------

Data are presented as mean ± standard error of the mean. Analysis of variance (ANOVA) with LSD post-hoc test was used to test the significance using SPSS^®^ for Windows, version 17.0.0 (SPSS, Inc., Chicago, IL, USA). For the cytotoxicity bar graph, a t-test was performed to compare the cytotoxicity of different concentrations to the control group and was described as the probability associated with a Student\'s paired t-test, with a two-tailed distribution. P\<0.05 was considered to indicate a statistically significant difference.

Results and Discussion
======================

Evaluation of the anticancer effect of MVN against MCF-7
--------------------------------------------------------

The MTT assay was used to assess the cytotoxicity of MVN against an MCF-7 solid tumor cell line. The treated MCF-7 cells showed an IC~50~ of 2.08 μg/ml after treatment with MVN ([Fig. 1](#f1-ijo-48-05-1886){ref-type="fig"}). This result indicated a promising cytotoxic effect relative to IC~50~ of the positive control DOX (0.42 μg/ml) reported previously by our laboratory ([@b17-ijo-48-05-1886]).

Caspase-3 activity in MCF-7 following treatment with IC~50~ of DOX and MVN
--------------------------------------------------------------------------

Concentrations of active caspase-3 were measured to determine whether the apoptotic cascade was activated. In MCF-7 cells, treatment with DOX significantly increased caspase-3 activity by 8-fold and MVN by 3-fold compared to its original activity ([Fig. 2](#f2-ijo-48-05-1886){ref-type="fig"}).

Transcript abundance analysis of MVN-treated cells with microarrays
-------------------------------------------------------------------

The aim of the experiment was to examine the gene expressions that are modulated using microarray in MVN-treated MCF-7 cells. To analyze the early stage of the pathway and network level, we treated MCF-7 cells with MVN for 4 h. The microarray analysis was performed to investigate genes associated with triggering apoptosis in the MVN-treated MCF-7 cells.

The quality of the microarray data were within good sample limits according to preliminary data analysis parameters, such as background and noise averages, percentage of present calls, presence of internal hybridization controls in increasing signals, presence of poly-A controls as decreasing signals and GAPDH to β-actin 30/50 signal ratios. Therefore, transcript abundance data were analyzed via the pathway following local normalization.

Cell-cycle arrest
-----------------

Several gene transcripts present in MCF-7 cells that were involved in the regulation of cell-cycle activity were significantly altered when exposed to MVN. In addition, changes in the related cell-cycle regulatory proteins were detected. Regulation of the cell cycle including the decrease of Rb and E2F1 transcript abundance was observed. EF2 is required for cell-cycle progression. Rb is also involved in cell-cycle regulation and can inhibit E2F. GADD45 transcripts, which control the G2/M phase transition, were also reduced by MVN treatment. MVN-induced DNA damage also had an impact on damage repair regulating pathways. One member of DNA-mismatch repair systems, MSH2, was significantly reduced in transcript abundance. PCNA, a cell proliferation marker and a control point for DNA repair, was also reduced. Cyclin-dependent kinases (CDKs) determine cell progression through the cell cycle. Both CDK1 (regulating G2 to S and G2 to M) and CDK4/6 (important for cell-cycle G1 phase progression) exhibited increased transcript abundance ([Table I](#tI-ijo-48-05-1886){ref-type="table"}).

Cell proliferation
------------------

MVN-induced inhibition of cell proliferation was observed in MCF-7 cells. Specifically, MVN inhibited HMG-CoA reductase and farnesyl pyrophosphate transferase, which reduced the biosynthesis of isoprenoids such as FPP and GGPP, crucial intermediates in cell signaling, and differentiation and proliferation. These results provide evidence that statins may have beneficial effects by increasing NOS expression and activity during the atherosclerotic process. MVN altered the transcript abundance of the Rho and RAP family of small GTPases that function as signal transduction, actin skeleton and cell shape factors. Overexpression was associated with cell proliferation and metastasis ([Table II](#tII-ijo-48-05-1886){ref-type="table"}).

Cellular metabolism
-------------------

MVN treatment altered the transcript abundance-encoding proteins involved in the regulation of metabolic processes such as pentose-phosphate shunt; 6-phosphogluconate dehydrogenase, 6-phosphogluconolactonase, phosphopentoseisomerase; glycolysis: phosphatetrioseisomerase, glyceratephosphomutase, dihydrolipyllysine residue acetyltransferase; fatty acid biosynthesis enzyme-encoding transcripts were reduced in transcript abundances including; hydrolase, lipoyl synthase, fatty acid synthase, acetyl Co-A carboxylase and acyl carrier protein. Transcripts encoding the tricarboxylic acid cycle; succinate dehydrogenase, isocitrate dehydrogenase, pyruvate carboxylase and ATP citrate lyase, responsible for the synthesis of cytosolic acetyl-CoA were also reduced ([Table III](#tIII-ijo-48-05-1886){ref-type="table"}).

MVN-induced oxidative stress and ROS generation
-----------------------------------------------

The transcript abundances of NADPH oxidase, peroxidase, glutathione peroxidase and glutathione reductase were increased, while the expression of superoxide dismutase was downregulated (an antioxidant enzyme) ([Table IV](#tIV-ijo-48-05-1886){ref-type="table"}).

Apoptosis and cell death
------------------------

MVN treatment was accompanied by the loss of cell viability. Functional clustering facilitated the identification and subsequent inclusion of a large group of proteins associated with apoptosis signaling. This group included tumor necrosis factor (*TNF*) family members, *TNFR* (*fas*), and *TNFRAP* (*TRADD*) activated by stress. In addition, the transcript abundance of p53 was increased. The p53 protein was involved in tumor suppression and was activated as a transcription factor in response to oncogene activation, hypoxia and DNA damage, resulting in growth arrest and/or apoptosis. Akt and MDM2 were decreased in abundance. Interaction of these proteins was central to p53 regulation. Several oncogenes were increased in transcript abundance including *Chk2*, *ATM*, *Ras* and *Raf*. MVN also altered the transcript abundance of pro-apoptotic genes (*BAX*, *NOXA*, *BID*, *APAF-1*), and the transcript abundance of antiapoptotic proteins, (*Bcl-2*, *Bcl-XL* and *AIP* or surviving). MVN increased the transcript abundance of cytochrome *c*. Transcript abundances of *P38* and *MAPK* were increased likely due to the transduction of extra cellular signals and stress. *CycD* (regulator for *CDK4* and *CDK6*) and *Cyc*, a transporter for organic ion, were increased in transcript abundance. *Caspase-8* and *-9* were increased in transcript abundance ([Table V](#tV-ijo-48-05-1886){ref-type="table"}).

The significance of statins in preventing various types of cancer has been previously reported ([@b18-ijo-48-05-1886]). Cholesterol and its draft is crucial for cell membrane stability and the synthesis of steroid hormones. Biomedical studies in the last two decades have demonstrated the influence of MVN and cholesterol metabolites on cell proliferation and growth. Increasingly, the geranylgeranyl pyrophosphate, another important mevalonate pathway product, is affected by statins and its targets Rho and Rac (small guanosine 5′-triphosphate binding proteins associated with Ras statins). This mevalonate pathway appears to be an important key in tumor apoptosis ([@b19-ijo-48-05-1886],[@b20-ijo-48-05-1886]).

Steroidogenesis and cholesterol transport were suggested to be essential for the growth and proliferation of tumor cells ([@b21-ijo-48-05-1886]). Steroidogenesis inhibition and the disruption of geranylgeranyl pyrophosphate-dependent survival pathways were attributed to the anti-proliferative effects of simvastatin, another HMGCo-A reductase inhibitor ([@b22-ijo-48-05-1886]). Additionally, the association between the statins in general and the low incidence of carcinogenesis supported this hypothesis ([@b11-ijo-48-05-1886]). Interference with the mevalonate pathway (prenylation) was known with its complexity to affect several apoptotic signaling pathways ([@b19-ijo-48-05-1886]). Furthermore, MVN and other statins affect cell viability via mixed apoptotic and necrotic pathways at the same time ([@b20-ijo-48-05-1886]). The efficacy of MVN against MCF-7 may be partly attributed to the multiplicity of its target signaling pathways ([Fig. 3](#f3-ijo-48-05-1886){ref-type="fig"}).

The safety profile of MVN in the experimental and clinical stages were encouraging for further clinical trials for the treatment of various types of tumors. The dose of MVN suggested for anti-cancer treatments was believed to be clinically safe ([@b6-ijo-48-05-1886],[@b7-ijo-48-05-1886]). Therefore, extremely high doses of MVN administered every 4 h to patients are considered tolerable ([@b19-ijo-48-05-1886]). Consequently, MVN and other natural statins may be an improved treatment option for cancer as compared to synthetic statins ([@b23-ijo-48-05-1886]).

MVN treatments inhibited DNA repair machinery, mRNA processing, translation and DNA recombination and induced cell cycle arrest. An increase in transcript abundances of GST (glutathione S-transferase) was observed. Although GST-Pi showed no significant alteration, it was active in the detoxification of ROS-induced damage. Increased NO levels and NOS were involved in generating oxidative stress. Cancer cells were more sensitive than normal cells to the effects of MVN on the transcript abundance of HMG-CoA reductase. HMG CoA reductase is able to alter some key cellular processes, inducing the multi-factorial stress caused by MVN.

The microarray results, showed that the physiological activity of MVN on apoptosis induction can be ascribed, not only to the p53 pathway, but also to additional mechanisms. Therefore, we undertook gene expression analysis using microarray. Apoptosis has received attention as a major mechanism of cell death in normal as well as tumor cells. However, programmed cell death may be interrupted due to defective signaling pathways in tumor cells with higher rates of mutation ([@b24-ijo-48-05-1886]). Defective apoptosis has been reflected in the cell resistance to apoptotic-inducing agents and, consequently, treatment failure. In addition, caspase-3 activity was measured and the results indicated that in the cancer cells treated with MVN the activity of caspase-3 was significantly increased. These findings were supported by transcript abundance analyses. Investigations from our group have previously shown that the apoptotic process in MVN-treated cells is mediated by differential transcript abundances, which is controlled by multi-factorial changes ([@b17-ijo-48-05-1886]). In this context, we conducted qPCR analysis of apoptosis-related genes in MVN-treated MCF-7 cells. Notably, the transcript abundances of a pro-apoptotic gene (*BAX*), an anti-apoptotic gene (*Bcl2*) and the key gene of apoptosis (*p53*) were quantified using the qPCR technique in MCF-7 cells treated for 72 h with the IC~50~ of the cytotoxic drug DOX or MVN ([@b17-ijo-48-05-1886]). It was found that there was increased *BcL2* but decreased BAX transcript abundance. By contrast, MVN treatment did not change the transcript abundance of *BAX*, but decreased the *BcL2* transcript abundance. Consequently, the p53 encoding transcript was increased in MVN-treated cells. In addition, MVN-treated cells were altered by oncogene expression, DNA damage, ROS generation or other forms of stress ([@b16-ijo-48-05-1886]).

MVN has been suggested to induce cell death via multiple apoptotic ([@b14-ijo-48-05-1886]), necrotic ([@b20-ijo-48-05-1886]) and autophagic pathways ([@b15-ijo-48-05-1886]). MCF-7 seemed to undergo apoptosis via the p53-dependent pathway. That finding is in concordance with that of a previous study by Lee and coworkers ([@b25-ijo-48-05-1886]) who demonstrated ameliorated cytotoxic effects of simvastatin in p53 knockdown clones of HCT116 colon cancer cell lines ([@b23-ijo-48-05-1886]). Similarly, the cytotoxic effects of MVN have been found in more than one cancer cell line and were p53-independent in nature ([@b26-ijo-48-05-1886],[@b27-ijo-48-05-1886]). This may also explain the ability of MVN to overcome K-Ras mutation in human non-small lung cancer ([@b16-ijo-48-05-1886]). Additionally, Freed-Pastor and colleagues ([@b28-ijo-48-05-1886]) studied the effects of mutated p53 on breast cancer cells. They showed that depletion of the mutated form of p53 reverses the oncogenic potential of breast cancer cell lines by inducing a normal-like phenotype characterized by the formation of acini-like structures.

In conclusion, MVN-induced antineoplastic effects against breast cancer cells were identified to be multi-factorial, possibly involving several regulatory pathways. The findings of the present study clearly support the potential use of MVN as a natural, safe and cost-effective anticancer drug compared to other traditional benchmarked chemotherapeutic drugs. Therefore, pre-clinical trials are fundamentally important to further investigate the selectivity of MVN and whether side effects may be present in healthy neoplasm-free cells. Furthermore, MVN efficacy and therapeutic potential may be maximized if this potential could be specifically delivered to the tumor mass.
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![The effect of mevinolin (MVN) on the MCF-7 cell line. (A and B) Cells were exposed to serial dilutions of MVN for 72 h. Cell viability was determined using an MTT assay. Data are presented as means ± standard deviation (n=3). The t-test was used to analyze the results of different MVN concentrations compared to the control group, ^\*^P\<0.5, ^\*\*^P\<0.1](IJO-48-05-1886-g01){#f1-ijo-48-05-1886}

![Effect of mevinolin (MVN) and doxorubicin (DOX) on the apoptosis effective phase (caspase-3 activity) in MCF-7 cells. Caspase-3 activity was assessed on MCF-7 cells following treatment with DOX and MVN. Data are presented as means ± standard deviation (n=3).](IJO-48-05-1886-g02){#f2-ijo-48-05-1886}

![Schematic diagram summarizing the effects of MVN on signaling pathways as found in the present study. Blue, significantly reduced transcript abundances. Red, increased transcript abundances. Red arrows, induction effects in protein expression or activity. Dotted arrows, inhibitory effects. MVN, mevinolin; TNFR, tumor necrosis factor receptor; TNFRAP, TNFR adaptor protein; P53, tumor suppressor protein p53; Casp7, 8 and 9, apoptosis-related cysteine peptidases 7, 8 and 9; MDM2, p53 binding protein homolog; BCL2, B-cell cell/lymphoma 2; Bim, BCL2-like 11 (apoptosis facilitator); ENDOG, endonuclease G; Cyt c, cytochrome *c*.](IJO-48-05-1886-g03){#f3-ijo-48-05-1886}

###### 

The gene list showing the fold-change of cell-cycle arrest-related genes.

  Entrez code   Gene symbol   Gene name                                                             Fold change   P-value
  ------------- ------------- --------------------------------------------------------------------- ------------- ---------
  9821          *RB1CC1*      RB1-inducible coiled-coil 1                                           −1.6          0.00008
  5925          *RB1*         Retinoblastoma 1                                                      −1.6          0.00168
  1869          *E2F1*        E2F transcription factor 1                                            1.4           0.00106
  83990         *BRIP1*       BRCA1 interacting protein C-terminal helicase 1                       −1.7          0.00073
  580           *BARD1*       BRCA1-associated RING domain 1                                        −1.3          0.00097
  890           *CCNA2*       Cyclin A2                                                             −1.1          0.09285
  9134          *CCNE2*       Cyclin E2                                                             −1.9          0.00040
  1029          *CDKN2A*      Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)   −1.1          0.18641
  1647          *GADD45A*     Growth arrest and DNA-damage-inducible, α                             −1.3          0.00575
  4616          *GADD45B*     Growth arrest and DNA-damage-inducible, β                             −1            0.04625
  4436          *MSH2*        MutS homolog 2, colon cancer, non-polyposis type 1 (*E. coli*)        −1.8          0.00060
  1019          *CDK4*        Cyclin-dependent kinase 4                                             1.1           0.00075

###### 

The gene list showing the fold-change of cell growth and proliferation-related genes.

  Entrez code   Gene symbol   Gene name                                                                               Fold-change   P-value
  ------------- ------------- --------------------------------------------------------------------------------------- ------------- ---------
  5111          *PCNA*        Proliferating cell nuclear antigen                                                      −1.1          0.13414
  2099          *ESR1*        Estrogen receptor 1                                                                     −1            0.00008
  3485          *IGFBP2*      Insulin-like growth factor binding protein 2, 36 kDa                                    1.1           0.00005
  3488          *IGFBP5*      Insulin-like growth factor binding protein 5                                            −1.1          0.02736
  1956          *EGFR*        Epidermal growth factor receptor \[erythroblastic leukemia viral (v-erb-b) oncogene\]   −1            0.04490
  2260          *FGFR1*       Fibroblast growth factor receptor 1                                                     −1            0.80737
  11116         *FGFR1OP*     FGFR1 oncogene partner                                                                  −1.3          0.00248
  7048          *TGFBR2*      Transforming growth factor, β receptor II (70/80 kDa)                                   −1.1          0.01276
  54509         *RHOF*        Ras homolog gene family, member F (in filopodia)                                        1.3           0.13142
  391           *RHOG*        Ras homolog gene family, member G (Rho G)                                               1.3           0.01589
  29984         *RHOD*        Ras homolog gene family, member D                                                       1.3           0.00112
  5911          *RAP2A*       RAP2A, member of RAS oncogene family                                                    −1.6          0.00088
  5912          *RAP2B*       RAP2B, member of RAS oncogene family                                                    −1.2          0.03266
  3156          *HMGCR*       3-hydroxy-3-methylglutaryl-CoA reductase                                                −1            0.0259
  2339          *FNTA*        Farnesyltransferase, CAAX box, α                                                        −1.4          0.00179
  2342          *FNTB*        Farnesyltransferase, CAAX box, β                                                        1.1           0.23093

###### 

The gene list showing the fold-change of cellular metabolism-related genes.

  Entrez code   Gene symbol   Gene name                                                       Fold-change   P-value
  ------------- ------------- --------------------------------------------------------------- ------------- ---------
  5226          *PGD*         Phosphogluconate dehydrogenase                                  1.5           0.00000
  6120          *RPE*         Ribulose-5-phosphate-3-epimerase                                −1.5          0.00002
  22934         *RPIA*        Ribose 5-phosphate isomerase A                                  −1.2          0.00570
  25796         *PGLS*        6-Phosphogluconolactonase                                       1.4           0.00000
  192111        *PGAM5*       Phosphoglyceratemutase family member 5                          1.4           0.48600
  7167          *TPI1*        Triosephosphateisomerase 1                                      1.2           0.00091
  1737          *DLAT*        Dihydrolipoamide S-acetyltransferase                            −1.3          0.00184
  11019         *LIAS*        Lipoic acid synthase                                            −1.2          0.10000
  2194          *FASN*        Fatty acid synthase                                             1.2           0.00983
  6389          *SDHA*        Succinate dehydrogenase complex, subunit A, flavoprotein (Fp)   1.2           0.04940
  3418          *IDH2*        Isocitrate dehydrogenase 2 (NADP+), mitochondrial               1.4           0.02310
  3420          *IDH3B*       Isocitrate dehydrogenase 3 (NAD+) β                             1.2           0.00194

###### 

The gene showing the fold change of ROS-related genes.

  Entrez code   Gene symbol   Gene name                                                 Fold-change   P-value
  ------------- ------------- --------------------------------------------------------- ------------- ---------
  10811         *NOXA1*       NADPH oxidase activator 1                                 1.2           0.17500
  2877          *GPX2*        Glutathione peroxidase 2 (gastrointestinal)               1.2           0.00675
  2878          *GPX3*        Glutathione peroxidase 3 (plasma)                         1.3           0.00412
  2879          *GPX4*        Glutathione peroxidase 4 (phospholipid hydroperoxidase)   1.3           0.00001
  2936          *GSR*         Glutathione reductase                                     1.1           0.00961
  6647          *SOD1*        Superoxide dismutase 1, soluble                           −1.1          0.00003
  4842          *NOS1*        Nitric oxide synthase 1 (neuronal)                        1.2           0.88300
  51070         *NOSIP*       Nitric oxide synthase interacting protein                 1.1           0.26400

ROS, reactive oxygen species.

###### 

The gene list showing the fold-change of apoptosis-related genes.

  -------------------------------------------------------------------------------------------------------------------
  Entrez code   Gene symbol   Gene name                                                       Fold-change   P-value
  ------------- ------------- --------------------------------------------------------------- ------------- ---------
  7157          *TP53*        Tumor protein p53                                               1.4           0.01360

  596           *BCL2*        B-cell CLL/lymphoma 2                                           −1.3          0.20900

  9530          *BAG4*        BCL2-associated athanogene 4                                    −1.3          0.00322

  7132          *TNFRSF1A*    Tumor necrosis factor receptor superfamily, member 1A           1.2           0.51300

  51330         *TNFRSF12A*   Tumor necrosis factor receptor superfamily, member 12A          1.2           0.00040

  8795          *TNFRSF10B*   Tumor necrosis factor receptor superfamily, member 10b          1.1           0.04220

  4982          *TNFRSF11B*   Tumor necrosis factor receptor superfamily, member 11b          −1.3          0.00413

  7128          *TNFAIP3*     Tumor necrosis factor, α-induced protein 3                      −1.4          0.96500

  84231         *TRAF7*       TNF receptor-associated factor 7                                1.2           0.00033

  9531          *BAG3*        BCL2-associated athanogene 3                                    1.1           0.00182

  663           *BNIP2*       BCL2/adenovirus E1B 19 kDa interacting protein 2                −1.4          0.00448

  1613          *DAPK3*       Death-associated protein kinase 3                               1.1           0.24500

  5134          *PDCD2*       Programmed cell death 2                                         −1            0.00509

  11235         *PDCD10*      Programmed cell death 10                                        −1.7          0.00005

  27250         *PDCD4*       Programmed cell death 4 (neoplastic transformation inhibitor)   1.3           0.00146

  4791          *NFKB2*       Nuclear factor of κ light polypeptide gene\                     1.1           0.04780
                              Enhancer in B-cells 2 (p49/p100)                                              

  208           *AKT2*        V-akt murine thymoma viral oncogene homolog 2                   1.2           0.01400

  64400         *AKTIP*       AKT-interacting protein                                         −1            0.00130

  4193          *MDM2*        Mdm2 p53 binding protein homolog (mouse)                        −1.1          0.04520

  23300         *ATMIN*       ATM interactor                                                  −1            0.00038

  472           *ATM*         Ataxia telangiectasia mutated                                   1             0.06510

  22821         *RASA3*       RAS p21 protein activator 3                                     −1            0.72500

  83593         *RASSF5*      Ras association (RalGDS/AF-6) domain family member 5            1.1           0.69500

  51285         *RASL12*      RAS-like, family 12                                             −1            0.03010

  158747        *MOSPD2*      Motile sperm domain containing 2                                −1.8          0.00022

  1111          *CHEK1*       CHK1 checkpoint homolog (*S. pombe*)                            1.2           0.01450

  5286          *PIK3C2A*     Phosphoinositide-3-kinase, class 2, α polypeptide               −1.8          0.04410

  8649          *MAPKSP1*     MAPK scaffold protein 1                                         −1.2          0.03410

  5594          *MAPK1*       Mitogen-activated protein kinase 1                              −1.1          0.10000

  5595          *MAPK3*       Mitogen-activated protein kinase 3                              1.3           0.00031

  5601          *MAPK9*       Mitogen-activated protein kinase 9                              1.1           0.00438

  5728          *PTEN*        Phosphatase and tensin homolog                                  −1.4          0.00057

  638           *BIK*         BCL2-interacting killer (apoptosis-inducing)                    1.2           0.12700

  53335         *BCL11A*      B-cell CLL/lymphoma 11A (zinc finger protein)                   −1            0.31100

  329           *BIRC2*       Baculoviral IAP repeat-containing 2                             −1.4          0.00026

  317           *APAF1*       Apoptotic peptidase activating factor 1                         1.1           0.57200

  1537          *CYC1*        Cytochrome c-1                                                  1.3           0.00097

  823           *CAPN1*       Calpain 1, (mu/I) large subunit                                 1.3           0.00552

  841           *CASP8*       Caspase-8, apoptosis-related cysteine peptidase                 1.1           0.03120

  837           *CASP4*       Caspase-4, apoptosis-related cysteine peptidase                 1             0.50200

  836           *CASP3*       Caspase-3, apoptosis-related cysteine peptidase                 −1.1          0.96700

  835           *CASP2*       Caspase-2, apoptosis-related cysteine peptidase                 1.1           0.15100

  2021          *ENDOG*       Endonuclease G                                                  1.4           0.00000

  842           *CASP9*       Caspase-9, apoptosis-related cysteine peptidase                 1.2           0.00003

  839           *CASP6*       Caspase-6, apoptosis-related cysteine peptidase                 −1.1          0.01460
  -------------------------------------------------------------------------------------------------------------------
